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Abstract: 
 
Two new polycyclic scaffolds were synthesized and evaluated as anti-influenza A 
compounds. The 5-azapentacyclo[6.4.0.02,10.03,7.09,11]dodecane derivatives were only 
active against the wild-type M2 channel in the low-micromolar range. However, some 
of the 14-azaheptacyclo[8.6.1.02,5.03,11.04,9.06,17.012,16]heptadecane derivatives were dual 
inhibitors of the wild-type and the V27A mutant M2 channels. The antiviral activity of 
these molecules was confirmed by cell culture assays. Their binding mode was analysed 
through molecular dynamics simulations, which showed the existence of distinct 
binding modes in the wild type M2 channel and its V27A variant.  
 
Keywords: 
 
Amantadine, polycyclic amines, influenza A, M2 channel, V27A mutant, molecular 
dynamics.
                                                 
 
 
Página 2 de 53 
 
Highlights 
 
a) Several polycyclic amines are synthesized as anti-influenza A virus. 
b) One of the syntheses presents a one-pot decarbonylation/intramolecular Diels-
Alder reaction. 
c) Compounds were examined as M2 channel blockers and anti-influenza A agents 
through in vitro tests. 
d) All the compounds were active against the wild-type M2 channel and two 
against the V27A mutant. 
e) Molecular simulations suggest distinct binding modes for the wild-type and 
V27A channels. 
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1. Introduction 
Influenza viruses cause the seasonal flu, which is worldwide associated with high 
socio-economic and medical burden [1]. Besides, influenza A virus possesses the 
capacity to cause sudden pandemics having higher mortality rates [2], such as the 
dreadful Spanish flu in 1918 [3,4] or the H1N1 pandemic in 2009 caused by a swine-
origin influenza virus [5–8]. There is also increased vigilance that highly pathogenic 
avian influenza viruses such as H5N1 [9] or H7N9 [10] may potentially acquire human-
to-human transmission, which may have devastating consequences. Though highly 
recommended for primary prophylaxis, the current influenza vaccines present several 
drawbacks [11], and hence antiviral drugs are equally vital for prevention and treatment 
of influenza infections. Only four anti-influenza drugs are available at this time: two 
neuraminidase inhibitors (oseltamivir and zanamivir) and two M2 channel blockers 
(amantadine, Amt, and rimantadine) [12]. Most of the circulating strains are Amt-
resistant [13,14], which has compelled the Centers for Disease Control and Prevention 
to deter its use [15]. On the other hand, oseltamivir resistance has also been spreading 
[16,17] and dual resistance to both oseltamivir and Amt has been detected [18]. These 
reasons have prompted the quest for new antivirals as effective ways of fighting 
influenza. 
The influenza A M2 polypeptide (A/M2) of 97 amino acids long, forms a 
homotetrameric proton channel that is critical for virus replication [19]. In the viral life 
cycle, A/M2 is crucial for acidification of the interior of the virus which is required for 
uncoating of the viral genetic material inside the host cell [20]. Furthermore, A/M2 
regulates the intralumenal pH of the Golgi apparatus and in this way prevents the 
premature conformational change of hemagglutinin, another key viral protein [21]. The 
A/M2 protein is also the target of Amt and hence Amt-resistant influenza strains bear a 
mutated Amt-insensitive M2 channel. Although many mutations appear to be viable in 
vitro [22,23], only three mutants comprehend more than 99% of the reported resistance 
[24,25], namely L26F, V27A and S31N. Despite the fact that the S31N amino acid 
substitution is predominant in more than 98% of the mutated M2 channels found in 
H3N2 viruses [26], the V27A mutant has been isolated in 10-77% of influenza viruses, 
depending on the viral strain and season [24,27]. Furthermore, the V27A mutant has 
proved to be the only one among the three most prevalent mutations to be originated 
from drug selection pressure [25]. Finally, while the S31N and L26F mutants are 
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sensitive, to some extent, to Amt, the latter is completely ineffective against the V27A 
mutant M2 channel. Therefore, there is great interest in the development of molecules 
capable of blocking multiple M2 channels to prevent the virus from finding an escape 
mechanism. 
Wu et al. have very recently reported the synthesis of N-[(5-bromothiophen-2-
yl)methyl]adamantan-1-amine, 1, the first dual inhibitor of wild-type (wt) and S31N 
mutant M2 channels [28]. Our work has been focused on the V27A mutant M2 channel, 
describing pyrrolidine 2, the most potent dual inhibitor of wt (IC50 = 3.4 µM) and V27A 
(IC50 = 0.29 µM) mutant M2 channels [29] (Figure 1). Last year, we reported the triple 
inhibitor 3, which is active against wt (IC50 = 18.0 µM), V27A (IC50 = 0.70 µM) and 
L26F (IC50 = 8.6 µM) mutant M2 channels [30]. Good activities against both wt (IC50 = 
2.1 µM) and V27A (IC50 = 22.6 µM) mutant M2 channels were found with polycyclic 
guanidine 4 [30] (Figure 1), which inspired us to derivatize it in pursue of potent 
inhibitors of the V27A A/M2 mutant protein. 
Herein we describe the syntheses and pharmacological evaluations of two families of 
polycyclic amines. One of them was designed with an enlarged scaffold with respect to 
4 in order to explore the chemical space around this skeleton, and the other features a 
new small polycyclic structure that was also assessed. All the novel compounds were 
low micromolar inhibitors of the wt M2 channel, and one of them was found to be a 
submicromolar inhibitor. Besides, amine 10 and guanidine 12 were active blockers of 
the V27A mutant M2 channel, but strikingly the amine derivative was more potent than 
the guanidine. 
 
Figure 1. 
 
2. Results and discussion 
2.1. Chemistry 
Our interest in modifying the polycyclic scaffold of Amt for developing novel M2 
channel blockers has led to the syntheses of ring-contracted, ring-rearranged and 2,2-
dialkyl derivatives of amantadine [31–34]. While exploring new carbon skeletons, we 
unveiled compound 4 as the only dual inhibitor of its family, with a low micromolar 
Página 5 de 53 
 
IC50 against wt M2 channel (IC50 = 2.1 µM), and a mid-range IC50 against the V27A 
mutant (IC50 = 22.6 µM) [30] (Figure 1). From previous molecular dynamics studies 
[30], we assumed that both wt and V27A M2 channels may accommodate larger 
molecules than 4. Since compound 4 was available in a few synthetic steps, we aimed at 
enlarging the molecule to evaluate its effects on the blockade of the M2 channels. On 
the other hand, we were also keen on the development of another small family of 
compounds easily available in a short synthetic sequence. 
The synthesis of the first set of compounds, derivatives of 4, started with known 
imide 5 easily accessed through the reaction of maleimide and cycloheptatriene [35]. 
The Diels-Alder reaction of 5 with 5,5-dimethoxy-1,2,3,4-tetrachlorocyclopentadiene 
furnished adduct 6 in 89% yield. This one was subjected to a one-pot 
dechlorination/deprotection reaction. The dechlorination was carried out by metallic 
sodium in liquid ammonia and an acidic deprotection of the acetal finally produced 
keto-imide 7 in 41% overall yield. Submitting 7 to 180 ºC in a sealed tube in the 
presence of hydroquinone as an antioxidant, produced polycyclic imide 8 through a one-
pot decarbonylation coupled with an intra-molecular Diels-Alder reaction [36], in 44% 
yield over the two steps (Scheme 1). Of note, the reaction started with the 
retrocheletropic extrusion of a molecule of carbon monoxide followed by two 
disrotatory retroelectrocyclic rearrangements that provided a molecule with the suitable 
configuration for the intramolecular Diels-Alder reaction (Scheme 2). Imide 8 was 
further reduced to amine 9, and was subsequently submitted to a catalytic hydrogenation 
to yield saturated amine 10. Both amines were transformed into their corresponding 
guanidines 12 and 11 respectively, after being reacted with 1H-pyrazole-1-
carboxamidine in moderate yields (Scheme 1). 
 
Scheme 1. 
Scheme 2. 
 
In order to explore other polycyclic scaffolds to assess their potential as M2 channel 
blockers, we also synthesized a second small set of compounds. Taking known diester 
13 as the first building block [37], a basic hydrolysis was performed upon this molecule 
to obtain diacid 14 in 86% yield. Unfortunately, we could not reproduce the 
photochemical reaction of 14 described in the literature to afford polycyclic structure 15 
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[37], even though the reaction was also attempted with the diester 13 and the anhydride 
of diacid 14. The synthesis was pursued with the hydrogenation of 14 at high pressure 
of hydrogen to furnish saturated diacid 16 [38] as the single endo-stereoisomer, which 
was confirmed with the X-ray diffraction analysis of a subsequent derivative. In turn, 16 
was reacted with urea at high temperature in order to secure imide 17 in 79% yield, 
which was further reduced to amine 18. The stereoisomerism of this family of 
compounds was unequivocally determined with the X-ray crystal structure of 18, which 
disclosed the endo-stereoisomer (Figure 2) [39]. Finally, amine 18 was transformed into 
the guanidine derivative 19 by reaction with 1H-pyrazole-1-carboxamidine (Scheme 3). 
Figure 2. 
Scheme 3. 
 
2.2. Inhibition of wt A/M2 and amantadine-resistant mutant ion channels 
The inhibitory activity of the compounds was tested on A/M2 channels expressed in 
Xenopus oocytes, using the two-electrode voltage clamp (TEVC) technique. All 
inhibitors were initially tested at 100 µM. Then, the compounds that inhibited either wt 
or V27A M2 channel activity by more than 70% were chosen for measurement of their 
IC50 value in an isochronic (2 min) inhibition assay. The results are given in Table 1. 
Table 1 
Amt inhibited the wt A/M2 channel with an IC50 of 16.0 µM, displayed less activity 
against the S31N mutant with an IC50 of 200 µM, and was totally inactive against the 
V27A variant. Amines 9 and 10 as well as guanidines 11 and 12 exhibited a low 
micromolar activity against the wt channel, but surprisingly, both amines were more 
active than their guanidine derivatives, a behaviour opposed to the results reported for 
previous sets of molecules [29,30]. The terminal insaturation seemed to have little to no 
effect on the activity against the wt M2 channel (9 vs. 10 or 11 vs. 12). However, 
against the V27A mutant, only the saturated compounds 10 and 11 displayed inhibitory 
activity, both being micromolar blockers of this M2 channel variant. Again, amine 10 
was more active than guanidine 11 (Table 1). Intriguingly, amine 10 was more active 
against the V27A mutant than its precursor guanidine 4 (Figure 1) while retaining the 
same activity against the wt channel. This confirmed our initial hypothesis about the 
potential optimization of this scaffold against the V27A mutant M2 channel. 
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Besides, compounds 18 and 19 were both, at least, low micromolar inhibitors of the 
wt channel, since guanidine 19, presenting a submicromolar activity, was more potent 
than its parent amine 18. Unfortunately, none of them were active against the V27A 
mutant. Neither of the tested molecules showed any relevant activity against the S31N 
mutant M2 channel. 
 
2.3. Molecular modeling 
The pharmacological profile of the size-expanded compounds 9 and 10, specifically 
as inhibitors of the V27A mutated channel, prompted us to explore their binding mode 
to the wt M2 channel and its V27A variant. To this end, a series of MD simulations 
were performed for the ligands bound to the M2 channels following the computational 
strategy reported previously for the binding of the Amt to both wt and V27A M2 
channels [30]. In particular, MD simulations were started from equilibrated structures of 
the channel embedded in a lipidic bilayer, and the ligand was located in the channel 
pore in the down orientation, which denotes that the protonated amine group is pointing 
toward the His plane (for details see Experimental details and ref. 30).   
The analysis of the MD simulations run for the wt M2 channel revealed a consistent 
binding mode for 9 and 10. Thus, the centre-of-mass (COM) of the ligand was located 
close to the plane formed by the S31 Cα atoms, with the amine nitrogen pointing to the 
H37 plane (average distance of 6.2 and 5.8 Å for 9 and 10, respectively; see Figures S1 
and S3 in Supplementary Material). Moreover, the tilt angle of the compounds, chosen 
as a measure of the deviation of the amine nitrogen from the pore axis, was 13.9 and 
17.6 degrees for 9 and 10, respectively (Figure 3). Overall, these trends resemble the 
binding mode reported for Amt in previous MD simulations [30] as well as in the 
crystallographic structure 2KQT [40], in agreement with the similar inhibitory activity 
of these inhibitors (Table 1). 
In contrast to these findings, the MD simulations run for the V27A channel suggest 
that compounds 9 and 10 adopt a distinct orientation, likely due to the wider pore of the 
channel [30]. Thus, in five out of six replicas run for 9 and 10 the inhibitor was found in 
the up binding mode, with the amine nitrogen oriented opposite to the plane formed by 
the H37 tetrad (Figure 3). The COM of the compounds was located between the planes 
formed by the Cα atoms of the S31 and A27 tetrads, the nitrogen amine was on average 
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located 15.3 and 15.0 Å from the H37 Cα plane for 9 and 10, respectively, and the tilt 
angle was close to 152 degrees for the two compounds (see Figures S2 and S4 in 
Supplementary Material).  
 
Figure 3. 
 
Previous molecular modeling studies showed that Amt also adopted the up binding 
mode in the V27A channel [30] and eventually was released from the channel pore, in 
agreement with the weak inhibition of the mutated channel (10.8% inhibition at 100 
µM; Table 1). In contrast to Amt, the MD simulations run for compounds 9 and 10 
support the stability of the up binding mode along the whole trajectory. This trend was 
also found for the binding of the pyrrolidine derivative 7,8,9,10-tetramethyl-3-
azapentacyclo[7.2.1.15,8.01,5.07,10]-tridecane 3 (Scheme 3; note that 3 corresponds to 
compound 18 in ref. 30). This agrees with the higher inhibitory potency of these 
compounds, as noted in IC50 values of 17.2 and 0.70 µM for 10 and 3, respectively. 
Noteworthy, the involvement of flipped orientations upon inhibitor binding to the wt 
M2 channel and its S31N variant has also been recently reported [28]. 
Compared to Amt, even though the size-enlargement of the hydrophobic cage has 
little effect on the inhibitory potency against the wt channel (IC50 values of 16.0, 2.6, 2.1 
and 18.0 µM for Amt, 9, 10 and 3, respectively), it affords a differential stabilization 
against the V27A channel. This trend can be attributed to the larger size of these 
compounds, as noted in molecular surfaces of 202, 255 and 260 Å2 for Amt, 9 and 10, 
respectively (molecular volumes of 220, 293 and 304 Å3 for Amt, 9 and 10), leading to 
a more stabilizing van der Waals interaction with the V27A channel (average values of -
21.3, -32.3 and-34.8 kcal/mol for Amt, 9 and 10, respectively, as determined from the 
snapshots sampled in the three replicas run for each inhibitor). On the other hand, the 
larger inhibitory potency of 10 could also reflect the increase in hydrophobicity 
resulting from saturation of the double bond present in 9, as noted in the logP values of 
4.8 and 4.3 estimated for 10 and 9 from IEF-MST computations. Note that this trend is 
also found in the guanidine derivatives 11 and 12, where the saturated compound also 
exhibits a larger hydrophobicity (estimated logP values of 3.2 and 2.5 for 11 and 12, 
respectively). 
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2.4. Antiviral activity and cytotoxicity in cell culture 
The anti-influenza virus activity of the compounds was first assessed in a relatively 
stringent three-day cytopathic effect (CPE) reduction assay in MDCK cells (Table 2). 
None of the tested compounds displayed any activity against the A/PR/8/34 strain 
bearing a doubly mutated M2 channel (V27T and S31N), in agreement with the TEVC 
results, nor against the A/HK/7/87 strain which carries a wt M2 channel. A plausible 
reason for the inactivity of compounds 9, 10, 11 and 12 against the A/HK/7/87 strain 
could be their poor selectivity, since all four compounds exhibited high cytotoxicity 
after 72 hr incubation with the cells. This was not the case for 18 and 19 (Table 2). 
None of the tested compounds was active against the influenza B virus B/HK/5/72 (data 
not shown). 
Table 2. 
We subsequently performed a 24-hr virus yield assay (based on RT-qPCR 
quantification of virus in the supernatant) and a virus plaque reduction assay (PRA), 
both using the wt M2 A/HK/7/87 virus. In the PRA, both amines 9 and 10 were found to 
be active in the same order of magnitude as Amt, but neither of the guanidines 11 nor 
12 showed any activity (Figure 4). With regard to the second family of compounds, 
only 18 was found to have intermediate antiviral activity, since guanidine 19 was 
completely inactive. For amine 10, the antiviral activity was close to its cytotoxic 
concentration (CC50; Table 2), meaning that it has a narrow selectivity index. The 
antiviral data in the PRA were confirmed with the virus yield assay, where amine 10 
was shown to be inactive as well as guanidines 11 and 12. On the other hand, amines 9 
and 18 exhibited visible antiviral activity giving 2-log10 reduction in virus yield. These 
combined in vitro data showed that 9 was the more potent compound, although 
associated with some cytotoxicity. The activity of 18 against the wt M2 channel, as seen 
in the TEVC studies, was supported by the cell culture assays with no visible 
cytotoxicity at the concentrations tested. 
Figure 4. 
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3. Conclusions 
Two novel series of size-expanded polycyclic amines and guanidines have been 
synthesized and tested as potential inhibitors of influenza A virus. The novel 
compounds were all low micromolar inhibitors of the wt M2 channel, and one of the 
guanidine derivatives (19) was found to be a submicromolar inhibitor with an IC50 value 
of 0.84 µM. On the other hand, amine 10 and guanidine 11 were active blockers of the 
V27A mutant M2 channel, but strikingly the amine derivative was more potent than the 
guanidine. Molecular modeling studies suggest a distinct binding mode for these Amt-
related analogues to the wt M2 channel and its V27A variant. Compared to Amt, the 
stronger inhibitory potency of these compounds seems to arise from the enhanced size 
of the hydrophobic cage of amine 10. The inhibitory activity of this compound was 
confirmed in the virus plaque reduction assay. 
 
4. Experimental section 
4.1. Plasmid, mRNA synthesis and microinjection of oocytes 
The cDNA encoding the influenza A/Udorn/72 (A/M2) was inserted into pSUPER 
vector for the expression on Xenopus oocyte plasma membrane. A/M2 S31N and A/M2 
V27A mutants were generated by QuikChange site-directed mutagenesis kit (Agilent 
Technologies). The synthesis of mRNA and microinjection of oocytes have been 
described previously [42]. 
 
4.2. Two-electrode voltage clamp analysis 
Macroscopic membrane current was recorded 24-72 hours after injection as 
described previously [43]. Oocytes were perfused at room temperature in Barth’s 
solution containing (in mM) 88 NaCl, 1 KCl, 2.4 NaHCO3, 0.3 NaNO3, 0.71 CaCl2, 
0.82 MgCl2, and 15 HEPES for pH 8.5 or 15 MES for pH 5.5 at a rate of 2 mL/min. The 
tested compounds were dissolved in DMSO and applied (100 μM) at pH 5.5 when the 
inward current reaches maximum. The compounds were applied for 2 min, and residual 
membrane current was compared with the membrane current before the application of 
compounds. Currents were recorded at −20 mV and analyzed with pCLAMP 8 software 
package (Axon Instruments, Sunnyvale, CA). 
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4.3. Antiviral evaluation in cell culture 
To determine the anti-influenza virus activity in Madin-Darby canine kidney 
(MDCK) cells, CPE reduction and virus yield assays were performed as described [41, 
44]. Briefly, MDCK cells grown in 96-well plates were infected with influenza virus 
[strains A/PR/8/34 (A/H1N1); A/HK/7/87 (A/H3N2) or B/HK/5/72], and at the same 
time the tested compounds were added in serial dilutions. After 72 h incubation at 35 
ºC, microscopy was performed to score the compounds’ inhibitory effect on viral 
cytopathic effect (CPE) as well as their cytotoxicity. These data were verified by 
measuring the cell viability with the formazan-based MTS assay. In separate 
experiments, supernatants were harvested from the infected and compound-treated cells 
at 24 h post infection, and virus yield in these samples was determined by RT-qPCR. To 
perform plaque reduction assays, influenza virus A/HK/7/87 was added together with 
different concentrations of the compounds, to confluent MDCK cells in 12-well plates. 
After 1 h incubation at 35°C, excess virus was removed and replaced by fresh medium 
containing the compounds and 0.8% agarose. After 72 h incubation, plaques were 
visualized by cell fixation with 3.7% formaldehyde and staining with 0.1% crystal 
violet. 
4.4. Cytotoxicity assays 
The compound cytotoxicity was assessed as described [44]. Briefly, exponentially 
growing MDCK cells were grown in 96-well plates and the test compounds were added 
in serial dilutions. After 72 h incubation at 35 °C, cell viability was measured by the 
formazan-based MTS assay and the OD values were used to calculate the compound 
concentrations causing 50% cytotoxicity (CC50). 
 
4.5. Chemistry 
4.5.1.  General 
Melting points were determined in open capillary tubes. NMR spectra were recorded 
in the following spectrometers: 1H NMR (400 MHz), 13C NMR (100.6 MHz). Chemical 
shits (δ) are reported in ppm related to internal tetramethylsilane (TMS) and coupling 
constants are reported in Hertz (Hz). Assignments given for the NMR spectra are based 
on DEPT, COSY 1H/1H, HETCOR 1H/13C (HSQC and HMBC sequences for one bond 
and long range 1H/13C heterocorrelations, respectively) and NOESY experiments for 
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selected compounds. For the MS and GC/MS analyses the sample was introduced 
directly or through a gas chromatograph. For GC/MS analyses a 30−meter column [5% 
diphenyl−95% dimethylpolysiloxane, conditions: 10 psi, initial temperature: 35 ºC (2 
min), then heating at a range of 8 ºC/min till 300 ºC, then isothermic at 300 ºC] was 
used. The electron impact (70 eV) or chemical ionization (CH4) techniques were used. 
Only significant ions are given: those with higher relative ratio, except for the ions with 
higher m/z values. Accurate mass measurements were obtained using ESI technic. 
Absorption values in the IR spectra (KBr or ATR) are given as wave-numbers (cm−1). 
Only the more intense bands are given. Column chromatography was performed on 
silica gel, 60 Å (35-70 mesh, SDS). For the thin layer chromatography (TLC) 
aluminum-backed sheets with silica gel 60 Å F254 were used and spots were visualized 
with UV light and/or 1% aqueous solution of KMnO4. 
  
4.5.2.   (1R, 2S, 3R, 4R, 7S, 8S, 9R, 10S, 11S, 15R)-4,5,6,7-Tetrachloro-
18,18-dimethoxy-13-azahexacyclo[8.5.2.14 ,7 .02 ,9 .03 ,8 .01 1 ,1 5]octadeca-
5,16-diene-12,14-dione (6) 
A mixture of 5 [35] (4.00 g, 19.88 mmol) and 5,5-dimethoxy-1,2,3,4-
tetrachlorocyclopentadiene (11.30 mL, 64.41mmol) were mixed in a sealed tube and 
heated to 140 ºC overnight. The brownish paste was concentrated under vacuo and the 
crude was purified by silica column chromatography. The EtOAc fractions carried 6 as 
a light yellow solid (8.23 g, 89%), mp> 300 ºC. IR ν 3366, 3048, 2987, 2948, 1761, 
1717, 1451, 1338, 1296, 1231, 1176, 1119, 1031, 981, 938, 830, 794, 777, 750, 702, 
661, 631, 611 cm-1. 1H NMR (400 MHz, CDCl3) δ: 2.11 [m, 2 H, 2(9)-H], 2.54 [m, 2H, 
3(8)-H], 2.74 [t, J = 1.2 Hz, 2 H, 11(15)-H], 3.26 [m, 2 H, 1(10)-H], 3.49 [s, 3H, -
OCH3], 3.51 [s, 3H, -OCH3], 6.43 [dd, J = 4.4 Hz, J’ = 3.2 Hz, 2 H, 16(17)-H], 7.95 
(broad s, 1 H, NH). 13C NMR (100.6 MHz, CDCl3) δ: 34.8 [CH, C1(10)], 38.1 [CH, 
C2(9)], 43.7 [CH, C11(15)], 50.4 [CH, C3(8)], 51.8 [CH3, -OCH3], 52.3 [CH3, -OCH3], 
76.7 [C, C4(7)], 128.8 (C, C18), 130.7 [C, C5(6)], 133.1 [CH, C16(17)], 177.7 [C=O, 
C12(14)]. MS (GC), rt = 31.1 min, m/e (%); main ions: 430 [(M-Cl) +, 100], 295 (12), 
281 (25), 255 (94), 207 (80), 179 (15), 112 (25), 103 (18), 78 (95), 59 (66). HRMS-
ESI+ m/z [M+H]+ calcd for [C19H17Cl4NO4+H]+: 463.9984, found: 463.9978. 
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4.5.3.  (1R, 2S, 3R, 4R, 7S, 8S, 9R, 10S, 11S)-13-
Azahexacyclo[8.5.2.14 ,7 .02 ,9 .03 ,8 .01 1 ,1 5]octadeca-5,16-diene-12,14,18-
trione (7).  
A solution of 6 (9.00 g, 19.3 mmol) in dry THF (60 mL) and dry MeOH (9 mL) was 
carefully added to freshly distilled ammonia (500 mL aprox.) at - 60 ºC. Sodium (5.6 g, 
24.2 mmol) was carefully added in small portions over 15 min. The  dark blue solution 
was stirred for another 15 min and it was quenched with NH4Cl. The white suspension 
was allowed to warm up to room temperature and was stirred overnight. The white 
precipitate was acidified with HCl aq. 10% (200 mL) and was left stirring for 1 hour. 
The white solution was extracted with DCM (3 x 150 mL), the organic phase was dried 
over Na2SO4, filtered and concentrated under vacuo. The white solid obtained was 
purified by silica column chromatography. In the (DCM : MeOH, 0.8%) fractions 7 was 
recovered as a white solid (2.24 g, 41%), mp 202-203 ºC. IR ν 3263, 3083, 3040, 2997, 
2939, 1795, 1780, 1695, 1363, 1297, 1226, 1193, 1104, 1067, 999, 941, 888, 879, 717, 
686 cm-1. 1H NMR (400 MHz, CDCl3) δ: 1.85 [m, 2 H, 2(9)-H], 2.33 [td, J = 3.2 Hz, J’ 
= 2 Hz, 2 H, 3(8)-H], 2.64 [t, J = 1.6 Hz, 2 H, 11(15)-H], 2.99 [quin, J = 2.8 Hz, 2 H, 
4(7)-H], 3.21 [m, 2 H, 1(10)-H], 6.46 [dd, J = 4.8 Hz, J’ = 3.2 Hz, 2 H, 16(17)-H], 6.80 
[t, J = 2 Hz, 5(6)-H],  8.03 (broad s, 1 H, NH). 13C NMR (100.6 MHz, CDCl3) δ: 35.2 
[CH, C1(10)], 37.5 [CH, C3(8)], 41.7 [CH, C2(9)], 43.9 [CH, C11(15)], 50.1 [CH, 
C4(7)], 133.8 [CH, C16(17)], 134.0 [CH, C5(6)], 178.2 [C=O, C12(14)], 200.0 (C=O, 
C18). MS (GC), rt = 24.5 min, m/e (%); main ions: 253 [(M-CO)·+, 53], 187 (14), 175 
(29), 165 (15), 155 (28), 128 (15), 116 (23), 104 (35), 91 (30), 78 (100). HRMS-ESI+ 
m/z [M+H]+ calcd for[C17H15NO3+H]+: 282.1125, found: 282.1118. 
4.5.4.  (1R, 2R, 3S, 4S, 5R, 6S, 9R, 10S, 11S, 12S, 16R, 17R)-14-
Azaheptacyclo[8.6.1.02 ,5 .03 ,1 104 ,9 .06 ,1 7.01 2 ,1 6]heptadec-7-ene-13,15-dione 
(8).  
A mixture of 7 (500 mg, 1.98 mmol) and hydroquinone (33 mg, 0.29 mmol) in a 
sealed tube was dissolved in xylene (50 mL). The white suspension was heated to 180 
ºC for 90 hours. The yellowish suspension was allowed to cool down to room 
temperature and was concentrated under vacuo. The solid obtained was purified through 
silica by column chromatography and 8 was collected in the (DCM 99.2: MeOH) 
fractions as a white solid (438 mg, 44%) that was used in the next step without further 
purification, mp 299-300 ºC. IR ν 3230, 3073, 1975, 1945, 2903, 2735, 1773, 1698, 
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1359, 1342, 1290, 1229, 1175, 1149, 1064, 1019, 938, 798, 741, 706, 686, 630 cm-1. 1H 
NMR (400 MHz, CDCl3) δ 1.76 (m, 2 H, 10(17)-H), 2.16 (m, 2 H, 1(11)-H), 2.33 (m, 2 
H, 4(5)-H), 2.55 (m, 2 H, 6(9)-H), 2.68 (m, 2 H, 2(3)-H), 2.81 (m, 2 H, 6(9)-H), 6.22 
[dd, J = 4.8 Hz, J’ = 3.2  Hz, 2H, 7(8)-H], 8.0 (broad s, 1 H, NH). 13C NMR (100.6 
MHz, CDCl3) δ: 34.3 [CH, C1(11)], 37.1 [CH, C12(16)], 37.6 [CH, C10(17)], 39.4 
[CH, C2(3)], 39.5 [CH, C4(5)], 39.8 [CH, C6(9)], 130.6 [CH, C7(8)], 180.2 [C, 
C13(15)]. MS (GC), rt = 24.6 min, m/e (%); main ions: 253 (M·+, 47), 187 (13), 182 
(12), 181 (12), 175 (26), 165 (14), 155 (26), 128 (15), 116 (22), 104 (34), 91 (27), 78 
(100). 
4.5.5.  (1R, 2R, 3S, 4S, 5R, 6S, 9R, 10S, 11S, 12S, 16R, 17R)-14-
Azaheptacyclo[8.6.1.02 ,5 .03 ,1 104 ,9 .06 ,1 7.01 2 ,1 6]heptadec-7-ene, 
hydrochloride (9·HCl) 
In a 3-necked round bottom flask fitted with a condenser and a thermometer, 8 (427 
mg, 1.69 mmol) was added under Ar atmosphere. Dry toluene (16 mL) was then poured 
and Red-Al 65% in toluene (2.60 mL, 8.43 mmol) was added dropwise. The solution 
was stirred at 107 ºC overnight. The solution was then allowed to cool down to room 
temperature and it was quenched with an aqueous 30% solution of KOH (15 mL) added 
dropwise. The organic phase was separated and the aqueous phase was extracted with 
DCM (3 x 35 mL). All the organic phases were put together, dried over anh. Na2SO4, 
filtered and concentrated under vacuo to give an orange oil (421 mg). The oil was 
dissolved in EtOAc and HCl/Et2O 0.66N was added until no more precipitate was 
formed. The suspension was filtered under vacuo and 9·HCl was recovered as an off-
white solid (325 mg, 74%). An analytical sample was obtained by crystallization from 
MeOH/Et2O, 282-283 ºC (dec.). IR ν 3041, 2918, 2902, 2726, 2602, 2484, 2376, 1594, 
1395, 1373, 1347, 1300, 1255, 910, 828, 809, 685 cm-1. 1H NMR (400 MHz, CD3OD) δ 
1.79 [broad s, 2 H, 1(11)-H], 1.87 [m, 2 H, 10(17)-H], 2.30 [m, 2 H, 4(5)-H], 2.44 [m, 2 
H, 12(16)-H], 2.54 [m, 2 H, 6(9)-H], 2.63 [m, 2 H, 2(3)-H], 3.12 [m, 2 H, 13(15)-Ha], 
3.56 [m, 2 H, 13(15)-Hb], 6.27 [dd, J = 4.6 Hz, J’ = 3.0 Hz, 2H, 7(8)-H]. 13C NMR 
(100.6 MHz, CD3OD) δ: 34.7 [CH, C12(16)], 36.7 [CH, C1(11)], 37.3 [CH, C10(17)], 
39.4 [CH, C2(3)], 40.8 [CH, C4(5)], 41.2 [CH, C6(9)], 51.4 [CH2, C13(15)], 131.9 [CH, 
C7(8)]. MS (DI), m/e (%); main ions: 225 (M·+, 100), 165 (9), 128 (9), 115 (16), 91 
(18), 80 (22), 78 (14), 68 (49). Anal. Calcd for C16H19N·HCl·0.25 H2O: C 72.16%, H 
7.76%, Cl 13.31, N 5.26. Found: C 72.16%, H 7.74%, Cl 13.25, N 5.07. 
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4.5.6.  (1R, 2R, 3S, 4S, 5R, 6S, 9R, 10S, 11S, 12S, 16R, 17R)-14-
Azaheptacyclo[8.6.1.02 ,5 .03 ,1 104 ,9 .06 ,1 7.01 2 ,1 6]heptadecane, hydrochloride 
(10·HCl) 
In an roundbottom flask 9·HCl (111 mg, 0.42 mmol) was dissolved in absolute 
EtOH (15 mL) and palladium on activated charcoal (235 mg, 5% in Pd) was added. The 
flask was fitted with a balloon filled with H2 at atmospheric pressure and the black 
suspension was stirred at room temperature overnight. It was then filtered and the clear 
solution was concentrated under vacuo to yield 10·HCl as a white solid (89 mg, 79%). 
An analytical sample was obtained by crystallization from MeOH/Et2O, mp 292-293 ºC 
(dec.). IR ν 2958, 2930, 2897, 2853, 2748, 2599, 2462, 1588, 1452, 1419, 1350, 1312, 
1290, 1262, 1049, 1025, 902, 825, 660 cm-1. 1H NMR (400 MHz, CD3OD) δ: 1.43 [m, 2 
H, 6(9)-H], 1.55 [m, 2 H, 7(8)-Ha], 1.63 [broad s, 2 H, 1(11)-H], 1.81 [m, 2 H, 7(8)-Hb], 
2.23 [m, 2 H, 10(17)-H], 2.44 [m, 2 H, 12(16)-H], 2.57-2.65 [complex signal, 4 H, 2(3)-
H and 4(5)-H], 3.19 [m, 2 H, 13(15)-Ha], 3.57 [m, 2 H, 13(15)-Hb]. 13C NMR (100.6 
MHz, CD3OD) δ: 19.9 [CH2, C7(8)], 34.7 [CH, C12(16)], 35.6 [CH, C6(9)], 36.8 [CH, 
C10(17)], 38.0 [CH, C1(11)], 39.9 [CH, C2(3)]*, 41.2 [CH, C4(5)]*, 51.6 [CH2, 
C13(15)]. MS (GC), m/e (%); main ions: 227 (M·+, 100), 155 (5), 141 (6), 128 (8), 117 
(10), 105 (5), 91 (19), 79 (11), 68 (10). Anal. Calcd for C16H21N·HCl·0.25H2O: C 
71.62%, H 8.45%, Cl 13.21%, N 5.22%. Found C 71.89%, H 8.49%, Cl 13.35%, N 
5.00%. 
4.5.7.  (1R, 2R, 3S, 4S, 5R, 6S, 9R, 10S, 11S, 12S, 16R, 17R)-14-Amidino-
14-azaheptacyclo[8.6.1.02 ,5 .03 ,1 104 ,9 .06 ,1 7.01 2 ,1 6]heptadec-7-ene, 
hydrochloride (12·HCl).  
A solution of 9·HCl (85 mg, 0.32 mmol) in water (10 mL) was basified to pH = 14 
with a 10 N aqueous solution of NaOH. It was then extracted with EtOAc (3 x 15mL) 
and the joined organic phase was dried over Na2SO4, filtered and concentrated under 
vacuo (yellow oil, 70 mg, 0.31 mmol, 96% yield). To a suspension of this oil in 
acetonitrile (3 mL), 1H-pyrazole-1-carboxamidine monohydrochloride (55 mg, 0.37 
mmol) was added. The suspension was heated to reflux for 6 hours. The suspension was 
allowed to cool down to 4 ºC and left at this temperature overnight. The yellow 
precipitate was filtered to give 12·HCl as an off-white solid (29 mg, 31%), mp 224-225 
ºC (dec.). IR ν 3309, 3125, 2940, 1635, 1627, 1375, 1351, 1295, 1255, 1182, 1147, 
1118, 1073, 828, 805, 690 cm-1. 1H NMR (400 MHz, CD3OD) δ 1.72 [complex signal, 4 
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H, 10(17)-H and 1(11)-H], 2.28 [m, 2 H, 4(5)-H], 2.47-2.55 [complex signal, 4 H, 6(9) 
and 12(16)-H], 2.61 [m, 2 H, 2(3)-H], 3.55-3.62 [complex signal, 4 H, 13(15)-H2], 6.25 
[dd, J = 4.8 Hz, J’ = 2.8 Hz, 2 H, 7(8)-H]. 13C NMR (100.6 MHz, CD3OD) δ 33.5 [CH, 
C12(16)], 36.4 [CH, C1(11)], 37.2 [CH, C2(3)], 37.9 [CH, C10(17)], 39.8 [CH, C4(5)], 
40.0 [CH, C6(9)], 52.0 [CH2, C13(15)], 130.5 [CH, C7(8)], 154.6 (C=NH). MS, m/e 
(%); main ions: 267 (M·+, 100), 266 (99), 225 (17), 224 (43), 165 (9), 117 (10), 115 
(16), 91 (17), 85 (63), 78 (15), 68 (32). HRMS-ESI+ m/z [M+H]+ calcd for 
[C17H22N3+H] +: 268.1808, found: 268.1811. 
4.5.8.  (1R, 2R, 3S, 4S, 5R, 6S, 9R, 10S, 11S, 12S, 16R, 17R)-14-Amidino-
14-azaheptacyclo[8.6.1.02 ,5 .03 ,1 104 ,9 .06 ,1 7.01 2 ,1 6]heptadecane 
hydrochloride,  (11·HCl).  
A solution of 10·HCl (82 mg, 0.31 mmol) in water (10 mL) was basified to pH = 14 
with a 10 N aqueous solution of NaOH. It was then extracted with EtOAc (3 x 15mL) 
and the joined organic phase was dried over Na2SO4, filtered and concentrated under 
vacuo (yellow oil, 67 mg, 0.29 mmol, 92% yield). To a suspension of this oil in 
acetonitrile (3 mL), 1H-pyrazole-1-carboxamidine monohydrochloride (52 mg, 0.29 
mmol) was added. The suspension was heated to reflux for 6 hours. The suspension was 
allowed to cool down to 4 ºC and left at this temperature overnight. The yellow 
precipitate was filtered to give 11·HCl as an off-white solid (38 mg, 42%), mp >300 ºC. 
IR ν 3300, 3176, 3118, 2945, 2900, 2856, 1628, 1458, 1298, 1258, 1098, 830, 729 cm-1. 
1H NMR (400 MHz, CD3OD) δ 1.39 [m, 2H, 6(9)-H], 1.55 [m, 4 H, 7(8)-Ha and 1(11)-
H], 1.78 [m, 2 H, 7(8)-Hb], 2.10 [broad s, 2 H, 10(17)-H], 2.52 [m, 2 H, 12(16)-H], 2.60 
[m, 4 H, 2(3)-H and 4(5)-H], 3.57-3.67 [complex signal, 4 H, 13(15)-H2]. 13C NMR 
(100.6 MHz, CD3OD) δ 19.9 [CH2, C7(8)], 35.0 [CH, C12(16)], 35.8 [CH, C6(9)], 37.4 
[CH, C10(17)], 40.4 [CH, C2(3)]*, 40.5 [CH, C1(11)]*, 40.7 [CH, C4(5)]*, 53.6 [CH2, 
C13(15)], 156.1 (C=NH). MS, m/e (%); main ions: 269 (M·+, 83), 226 (57), 141 (6), 129 
(8), 117 (10), 91 (18), 85 (C3H7N3·+, 100), 79 (11), 68 (11). HRMS-ESI+ m/z [M+H]+ 
calcd for [C17H24N3+H] +: 270.1965, found: 273.1963. 
4.5.9.  (2R, 3S, 7R, 8S, 9S, 10R)-5-
Azapentacyclo[6.4.0.02 ,1 0.03 ,7 .09 ,1 1]dodecane-4,6-dione (17) 
A mixture of 16 [38] (1.03 g, 4.95 mmol) and urea 99.5% (1.49 g, 24.7 mmol) was 
heated to 150ºC until the urea melted. Then the temperature was raised to 220ºC for 30 
min. The brown paste was redissolved in water (50 mL) and DCM (50 mL). The first 
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organic phase was separated and the aqueous phase was extracted with DCM (5x50 
mL). The combined organic phases were dried over Na2SO4, filtered and concentrated 
under reduced pressure to yield 17 as a yellow solid (737 mg, 79%), mp 211-212 ºC. IR 
ν 3446, 3185, 3064, 2953, 2931, 2864, 2737, 1750, 1705, 1384, 1354, 1327, 1312, 
1289, 1261, 1223, 1178, 1121, 1072, 1001, 993, 936, 797, 749, 706, 650, 632, 604, 538 
cm-1. 1H NMR (400 MHz, CDCl3) δ 1.08 [dd, J = 4.8 Hz, J’ = 0.8 Hz, 2 H, 9(10)-H, 
1.26 (t, J = 4.8 Hz, 1 H, 11-H), 1.59 (t, J = 1.2 Hz, 2 H, 12-H2), 2.11 (broad s, 1 H, 1-
H), 2.45 [broad s, 2 H, 2(8)-H], 3.24 [dd, J = 3.2 Hz, J’ = 2.0 Hz, 2 H, 3(7)-H], 8.40 
(broad s, 1 H, NH). 13C NMR (100.6 MHz, CDCl3) δ 11.2 [CH, C9(10)], 12.8 (CH, 
C11), 31.2 (CH2, C12), 44.2 [CH, C3(7)], 45.6 (CH, C1), 48.8 [CH, C2(8)], 179.1 
[C=O, C4(6)]. MS (GC), m/e (%); main ions: 189 (M·+, 67), 118 (92), 117 [(M-
C2H2NO2)·+, 100], 115 (23), 92 (11), 91 (28), 65 (9), 58 (9). HRMS-ESI+ m/z [M+H]+ 
calcd for [C11H11NO2+H] +: 190.0863, found: 190.0867. 
4.5.10.  (2R, 3S, 7R, 8S, 9S, 10R)-5-
Azapentacyclo[6.4.0.02 ,1 0.03 ,7 .09 ,1 1]dodecane hydrochloride (18·HCl) 
To a solution of 17 (627 mg, 3.31 mmol) in dry toluene (22 mL) was added dropwise 
Red-Al 65% in toluene (5.05 mL, 16 .57 mmol). The mixture was heated to reflux for 
2 days. The black solution was quenched with KOH 30% aq. (10 mL) and the first 
organic phase was separated. The aqueous layer was extracted with DCM (3x20 mL) 
and the combined organic phases were dried over Na2SO4, filtered and concentrated 
under reduced pressure. The yellow oil was redissolved in EtOAc and HCl/Et2O 1.2N 
was added until no more precipitate was formed. It was filtered under vacuo and the 
light brown residue was recovered as 18·HCl (305 mg, 47%), mp 208-209 ºC. IR ν 
3435, 3209, 3081, 3046, 2983, 2899, 2954, 2938, 2870, 2752, 2725, 2620, 2559, 2443, 
1569, 1467, 1457, 1399, 1344, 1305, 1274, 1256, 1231, 1146, 1062, 1000, 987, 945, 
890, 875, 830, 817, 770, 695, 654 cm-1. 1H NMR (400 MHz, CD3OD) δ 1.16 [d, J = 5.2 
Hz, 2 H, 9(10)-H], 1.31 (t, J = 5.2 Hz, 1 H, 11-H), 1.56 (t, J = 1.2 Hz, 2 H, 12-H2), 2.11 
(m, 1 H, 1-H), 2.13 [m, 2 H, 2(8)-H], 3.00 [dd, J = 7.2 Hz, J’ = 3.2 Hz, 2 H, 3(7)-H], 
3.24 [m, 2 H, 4(6)-Ha], 3.42 [dd, J = 12 Hz, J’ = 3.2 Hz, 2 H, 4(6)-Hb]. 13C NMR (100.6 
MHz,  CD3OD) δ 11.4 [CH, C9(10)], 15.2 (CH, C11), 31.4 (CH2, C12), 45.2 [CH, 
C3(7)], 46.9 (CH, C1), 47.3 [CH, C2(8)], 49.0 [CH2, C4(6)]. MS (DI), m/e (%); main 
ions: 162 (10), 161 (M·+, 84), 160 (56), 132 (14), 131 (12), 129 (12), 120 (20), 118 (21), 
117 (47), 116 (13), 115 (30), 107 (18), 106 (17), 95 (28), 94 (50), 93 (15), 58 (91), 83 
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(14), 82 (28), 81 (35), 80 (90), 79 (16), 78 (27), 78 (26), 69 (11), 68 (100), 67 (25), 65 
(18), 56 (12), 51 (11). Anal. Calcd for C11H15N·HCl·0.3H2O·0.15HCl: C 63.34, H 8.09, 
Cl 19.55, N 6.72. Found: C 63.30, H 8.04, Cl 19.78, N 6.71.  
4.5.11.  (2R, 3S, 7R, 8S, 9S, 10R)-5-Amidino-5-
azapentacyclo[6.4.0.02 ,1 0.03 ,7 .09 ,1 1]dodecane hydrochloride (19·HCl) 
A mixture of 18·HCl (305 mg, 1.54 mmol), 1H-pyrazole-1-carboxamidine 
monohydrochloride (271 mg, 1.85 mmol) and triethylamine (0.4 mL, 2.78 mmol) was 
dissolved in acetonitrile (12 mL). The yellow suspension was heated to mild reflux for 6 
hours. The suspension was allowed to cool down a bit and the flask was sealed and left 
at 4 ºC overnight. The yellow liquid phase was poured out from the flask and 19·HCl 
was recovered as a light orange solid (258 mg, 70%). An analytical sample was 
crystallized from isopropanol, mp 153-154 ºC. IR ν 3567, 3482, 3344, 3304, 3190, 
3138, 3066, 2995, 2958, 2945, 2881, 2861, 2677, 1627, 1508, 1467, 1458, 1367, 1342, 
1304, 1284, 1249, 1225, 1189, 1160, 1073, 1036, 957, 937, 832, 802, 787, 775, 644, 
582 cm-1. 1H NMR (400 MHz, CD3OD) δ 1.00 [dd, J = 5.2, J’ = 0.8 Hz, 2 H, 9(10)-H], 
1.20 (t, J = 5.2 Hz, 1 H, 11-H), 1.55 (t, J = 1.2 Hz, 2 H, 12-H2), 2.02 (broad s, 1 H, 1-
H), 2.13 [broad s, 2 H, 2(8)-H], 2.97 [m, 2 H, 3(7)-H], 3.39 [m, 2 H, 4(6)-Ha], 3.65 [dd, 
J = 10.8 Hz, J’ = 1.2 Hz, 2 H, 4(6)-Hb]. 13C NMR (100.6 MHz, CD3OD) δ 10.7 [CH, 
C9(10)], 13.9 (CH, C11), 31.5 (CH2, C12), 44.8 [CH, C3(7)], 45.9 (CH, C1), 48.5 [CH, 
C2(8)], 50.1 [CH2, C4(6)], 155.7 [C=NH]. MS (DI), m/e (%); main ions: 204 (15), 203 
(M·+, 100), 202 (13), 160 (49), 137 (13), 131 (10), 129 (28), 128 (14), 124 (19), 117 
(25), 116 (12), 115 (26), 111 (39), 110 (97), 95 (11), 94 (21), 93 (12), 91 (49), 85 (51), 
82 (17), 80 (24), 79 (14), 78 (15), 77 (23), 72 (20), 68 (68), 67 (14), 65 (16). Anal. 
Calcd for C12H17N3·HCl·0.75H2O·0.05HCl: C 56.50, H 7.73, Cl 14.59, N 16.47. Found: 
C 56.55, H 7.59, Cl 14.49, N16.62. 
4.6. Molecular modeling 
4.6.1. Molecular dynamics simulations 
The binding mode of compounds 9 and 10 to the wt M2 channel and its V27A 
variant embedded on a model bilayer of 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) was studied by MD simulations. The M2 channel was modeled 
from the solid state NMR structure obtained by Sharma et al. (PDB entry 2L0J) [45], 
and it was oriented using as template the solid state NMR structure with PDB entry 
2KQT [40] as deposited in the Orientations of Proteins in Membranes (OPM) database 
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[46]. The X-ray crystallographic structure 3LBW [47] from the Protein Data Bank was 
used to model the position of water molecules inside the channel. The initial position of 
the ligand was chosen to resemble the orientation of Amt in the 2KQT structure. 
The CHARMM-GUI [48] web server was used to build up the initial systems. 
Briefly, the complex formed by the protein, the inner lumen water molecules, and the 
ligand was embedded on a 100 Å × 100 Å POPC bilayer patch. A 25 Å layer of TIP3P 
[49] water molecules was set up at both sides of the bilayer, and K+ cations and Cl– 
anions were added to achieve an ionic strength of 150 mM. The Parm99SB [50] force 
field was used for the protein, the ligands were parametrized using the gaff [51] force 
field in conjunction with RESP HF/6-31G(d) charges as implemented in the 
Antechamber module of AMBER12 software package [52], and the POPC molecules 
were parametrized according to the gaff-lipid11 force field [53]. Joung and Cheatham 
parameters were used to model the counterions [54]. Each system comprised around 
97000 atoms, including the protein ligand complex, 265 POPC molecules, around 
58000 waters and 108 (51 K+; 57 Cl–) counterions in a simulation box of 100000 Å3. 
The geometry of the system was minimized in five cycles that combined 3500 steps 
of steepest descent algorithm followed by 4500 of conjugate gradient. Thermalization of 
the system was performed in 5 steps of 1 ns, where the temperature was gradually 
increased from 50 K to 298 K, while the protein, ligand, and POPC molecules were 
restrained with a force constant of 1 kcal mol–1 Å–2. Prior to the production runs, a set of 
20 ns MD simulations was performed to smoothly equilibrate the systems by gradually 
reducing the restraints first for the POPC molecules (restraints reduced by 0.1 kcal mol–
1 Å–2 at each step) and then for the protein (restraints reduced by 0.2 kcal mol–1 Å–2 at 
each step). At this point, three different replicas were generated for each ligand–protein 
complex (accounting for a total of 12 different simulation systems). 
We took advantage of the GPU-accelerated PMEMD module from AMBER12 
software package for the production runs, which consisted of 50 ns trajectories 
(accounting for a global simulation time of 600 ns) using SHAKE for bonds involving 
hydrogen atoms, a time step of 2 fs, periodic boundary conditions using anisotropic 
constant pressure and temperature (298 K; Langevin thermostat with a collision 
frequency of 3 ps–1), particle mesh Ewald for long-range electrostatic interactions, and a 
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cutoff of 10 Å for nonbonded interactions. The analysis of the trajectories was 
performed for snapshots taken every 5 ps. 
 
 
 
4.6.2. Log P calculation 
The octanol/water partition coefficient (log P) of Amt and compounds 9-12 was 
determined by means of QM calculations at B3LYP/6-31G(d) basis set. We first 
optimized the structure of each compound in their neutral state in gas phase, and then a 
single-point calculation was performed in water and octanol using the B3LYP-
parametrized version of the IEF/MST continuum solvation model [55]. Calculations 
were performed using a locally modified version of Gaussian09 [56]. 
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LEGENDS FOR FIGURES AND SCHEMES 
 
 
Figure 1. Structures of amantadine, rimantadine and some reported compounds 
with potent activities against the wt, S31N and/or V27A mutantsa 
aThe IC50 values shown correspond to the 50% inhibitory concentrations determined by 
TEVC assay. The inhibition percentages shown were determined at 100 µM for 2 min 
by TEVC [28,29]. N.T: Not Tested. 
 
Scheme 1. Synthesis of new polycyclic amines 9 and 10 and guanidine derivatives 
11 and 12 
a: sealed tube, neat, 140 ºC, overnight (89%); b: sodium, liquid NH3, dry THF, dry 
MeOH, -60 ºC, 30 min; c: HCl 10%, water, room temperature, 1h (41 % overall); d: 
hydroquinone, sealed tube, xylene, 180 ºC, 90h (44% overall); e: Vitride, dry toluene, 
reflux, overnight (74%); f: H2, 1atm, Pd/C, absolute EtOH, room temperature, overnight 
(79%); g: 1H-pyrazole-1-carboxamidine, Et3N, ACN, reflux, 6h (42% for 11, 31% for 
12).  
 
Scheme 2. Mechanism of the one-pot decarbonylation coupled with intramolecular 
Diels-Alder reaction of 7 
 
Figure 2. Crystal structure (ORTEP) of 18·HCl. Thermal ellipsoids shown at 50% 
probability 
 
Figure 3. Representation of the predicted binding mode of compounds 9 and 10 
(shown as orange and yellow sticks, respectively) to the interior of the wt M2 channel 
and its V27A variant. The side chains of pore-lining residues are shown and labelled. 
 
Scheme3. Synthesis of the second family of compounds including amine 18 and 
guanidine 19 
a: H2, 400 psi, Pd/C, absolute EtOH, room temperature, 2 days (90%); b: urea, neat, 150 
ºC then 200 ºC, 30 min (79%); c: vitride, dry toluene, reflux, 2 days (47%); d: 1H-
pyrazole-1-carboxamidine, Et3N, ACN, reflux, 6h (70%). 
 
Table 1. Inhibitory effect of the synthesized compounds on proton channel 
functiona of wt, S31N or V27A mutant A/M2 proteins 
a Isochronic (2 min) values for IC50 are given. See text and experimental section for 
further details. bND: Not Determined. 
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Table 2. Antiviral activity in influenza virus-infected MDCKa cells. 
aMDCK: Madin-Darby canine kidney cells; virus strains: A/PR/8/34 (A/H1N1) and 
A/HK/7/87 (A/H3N2). b50% effective concentration, or compound concentration 
producing 50% inhibition of virus replication, as determined by microscopic scoring of 
the CPE at 72 h post infection, or by the MTS cell viability test. cEC50: concentration at 
which the plaque number is reduced by 50% compared to untreated virus control in the 
virus plaque reduction assay (PRA). dEC99: compound concentration giving 2-log10 
reduction in virus yield, as determined by quantifying the virus in the supernatant at 24 
h post infection, using an RT-qPCR based virus yield assay [41]. eCC50: 50% cytotoxic 
concentration, as determined by the MTS cell viability test. fMCC: minimum cytotoxic 
concentration, or concentration producing minimal alterations in cell morphology after 
72 h incubation with compound. Values shown are the mean of 2-3 determinations. 
 
Figure 4. Activity of the compounds in an influenza virus plaque reduction assay. 
MDCK cells were infected with influenza virus (strain A/HK/7/87; 25 PFU per well) in 
the presence of the test compounds. After 72 h incubation, plaques were visualized by 
crystal violet staining. VC: mock-treated virus control; CC: uninfected cell control. 
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Compound 
A/M2 wt (mean ± SE) A/M2 S31N (mean ± SE) A/M2 V27A (mean ± SE) 
Inhibition by 
100 µM for    
2 min (%) 
IC50 
(µM) 
Inhibition by 
100 µM for 2 
min (%) 
IC50 
(µM) 
Inhibition by 
100 µM for 2 
min (%) 
IC50 
(µM) 
Amantadine 91.0 ± 2.1 16.0 ± 1.2 35.6 ± 1.5 199.9 ± 13.5 10.8 ± 2.0 NDb 
4 94.5 ± 1.6 2.1 2.6 ± 1.4 ND 75.9 ± 1.2 22.6 
9 96.4 ± 1.3 2.6 0 ND 49.0 ± 2.8 ND 
10 98.1 ± 0.5 2.1 0 ND 83.9 ± 0.7 17.2 
11 90.6 ± 3.1 3.7 4.7 ± 0.7 ND 71.2 ± 3.9 32.2 
12 89.6 ± 0.9 6.9 0 ND 54.0 ± 0.6 ND 
18 93.7 ± 0.8 3.3 0 ND 0 ND 
19 99.0 ± 0.5 0.84 2.0 ± 1.1 ND 0 ND 
 
Table 1. 
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 Antiviral activity (µM)  
 A/PR/8/34  A/HK/7/87  Cytotoxicity (µM) 
Compound EC50 
(CPE)b 
EC50 
(MTS)b 
 EC50 
(CPE)b 
EC50 
(MTS)b 
EC50 
(PRA)c 
EC99 
(Yield)d 
 CC50e MCCf 
9 >100 >100  >100 >100 0.37 3.45  11 20 
10 >100 >100  >100 >100 0.54 >2  3.7 4.0 
11 >100 >100  >100 >100 >5 >2  4.6 7.0 
12 >100 >100  >100 >100 >5 >2  1.2 2.0 
18 >100 >100  >100 >100 6.7 28  >100 >100 
19 >100 >100  >100 >100 >100 >50  50 >100 
Amantadine 30 34  1.4 1.4 0.14 0.72  >500 ≥500 
Rimantadine 7.6 5.1  0.81 0.15 0.02 1.77  230 500 
 
Table 2. 
S37 
 
 
 
Figure 4. 
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X-Ray crystallographic data 
 
Crystal structure report for 18·HCl 
 
A prismatic crystal of C12H17N3·HCl (0.1x0.1x0.2 mm) was selected and mounted on a 
MAR345 diffractometer with an image plate detector. Unit-cell parameters were 
determined from 783 reflections (3 < θ < 31º) and refined by least-squares method. 
Intensities were collected with graphite monochromatized Mo Kα radiation, using ϕ 
scan-technique.15743 reflections were measured in the range 1.53 ≤ θ ≤ 30.93. 2695 of 
which were non-equivalent by symmetry (Rint(on I) = 0.030 ). 2478 reflections were 
assumed as observed applying the condition I > 2  σ(I). Lorentz-polarization and 
absorption corrections were made.  
 
The structure was solved by Direct methods, using SHELXS computer program 
(Sheldrick, G.M., (1997), Crystallogr. 2008, A64, 112) and refined by full-matrix least-
squares method with SHELX97 computer program (Sheldrick, G.M., (1997), 
Crystallogr. 2008, A64, 112), using 126 reflections, (very negative intensities were not 
assumed). The function minimized was Σ w ||Fo|2 - |Fc|2 |2, where w = [σ2(I) + 
(0.0339P)2+1.5332P]-1, and P = (Fo|2 + 2 |Fc|2 )/3, f, f' and f" were taken from 
International Tables of X-Ray Crystallography (International Tables of X-Ray 
Crystallography, (1974), Ed. Kynoch press, Vol. IV, pp 99-100 and 149).  
 
2H atoms were located from a difference synthesis and refined with isotropic 
temperature factor and 14H atoms were computed and refined, using a riding model, 
with isotropic temperature factor equal to 1.2 time the equivalent temperature factor of 
the atom which are linked. The final R(on F) factor was 0.040, wR(on |F|2) =  0.098 and 
goodness of fit = 1.162 for all observed reflections. Number of refined parameters was 
126. Max. shift/esd = 0.00, Mean shift/esd = 0.00. Max. and min. peaks in final 
difference synthesis was 0.138 and -0.168 eÅ-3, respectively. 
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Figure S1. Selected geometrical parameters (distances in Å; tilt angle in degrees) for 
the binding of compound 9 to the wt M2 channel along the trajectories sampled for the 
three 50 ns MD replicas. Left: Distance from the amine N to the His37 plane and tilt 
angle (defined as the angle between amine N, COM of ligand, and COM of His37 Cα 
atoms). Right: Distances from the COM of ligand to the plane formed by tetrads of 
residues along the pore. 
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Figure S2. Selected geometrical parameters (distances in Å; tilt angle in degrees) for 
the binding of compound 9 to the V27A mutant M2 channel along the trajectories 
sampled for the three 50 ns MD replicas. Left: Distance from the amine N to the His37 
plane and tilt angle (defined as the angle between amine N, COM of ligand, and COM 
of His37 Cα atoms). Right: Distances from the COM of ligand to the plane formed by 
tetrads of residues along the pore. 
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Figure S3. Selected geometrical parameters (distances in Å; tilt angle in degrees) for 
the binding of compound 10 to the wt M2 channel along the trajectories sampled for the 
three 50 ns MD replicas. Left: Distance from the amine N to the His37 plane and tilt 
angle (defined as the angle between amine N, COM of ligand, and COM of His37 Cα 
atoms). Right: Distances from the COM of ligand to the plane formed by tetrads of 
residues along the pore. 
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Figure S4. Selected geometrical parameters (distances in Å; tilt angle in degrees) for 
the binding of compound 10 to the V27A mutant M2 channel along the trajectories 
sampled for the three 50 ns MD replicas. Left: Distance from the amine N to the His37 
plane and tilt angle (defined as the angle between amine N, COM of ligand, and COM 
of His37 Cα atoms). Right: Distances from the COM of ligand to the plane formed by 
tetrads of residues along the pore. 
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